AngioDynamics, Inc. (NASDAQ:ANGO) issued an update on its FY18 earnings guidance on Tuesday morning. The company provided EPS guidance of $0.64-0.68 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.68. The company issued revenue guidance of $352-359 million, compared to the consensus revenue estimate of $357.75 million.
Shares of AngioDynamics, Inc. (NASDAQ:ANGO) opened at 16.38 on Friday. The firm has a 50-day moving average of $16.08 and a 200-day moving average of $16.22. The firm’s market capitalization is $602.46 million. AngioDynamics, Inc. has a one year low of $14.80 and a one year high of $18.18.
AngioDynamics (NASDAQ:ANGO) last released its earnings results on Tuesday, July 18th. The medical instruments supplier reported $0.19 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.16 by $0.03. The firm had revenue of $86.90 million for the quarter, compared to analysts’ expectations of $90.72 million. AngioDynamics had a return on equity of 5.19% and a net margin of 2.00%. The business’s quarterly revenue was down 7.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.19 EPS. On average, equities analysts predict that AngioDynamics, Inc. will post $0.67 earnings per share for the current fiscal year.
Several research firms have commented on ANGO. Cantor Fitzgerald set a $21.00 target price on AngioDynamics and gave the company an overweight rating in a research note on Thursday, April 6th. Canaccord Genuity restated a hold rating and issued a $16.50 target price on shares of AngioDynamics in a research note on Wednesday, May 31st. Zacks Investment Research cut AngioDynamics from a buy rating to a hold rating in a research note on Monday, April 10th. Craig Hallum set a $20.00 target price on AngioDynamics and gave the company a buy rating in a research note on Saturday, April 1st. Finally, Barclays PLC cut their target price on AngioDynamics from $17.00 to $16.00 and set an equal weight rating on the stock in a research note on Wednesday, July 19th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of $18.50.
In related news, CEO James C. Clemmer purchased 20,000 shares of the stock in a transaction on Thursday, July 20th. The shares were purchased at an average price of $15.64 per share, with a total value of $312,800.00. Following the transaction, the chief executive officer now directly owns 86,683 shares of the company’s stock, valued at $1,355,722.12. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO James C. Clemmer purchased 5,000 shares of the stock in a transaction on Friday, July 21st. The shares were bought at an average cost of $15.79 per share, for a total transaction of $78,950.00. Following the transaction, the chief executive officer now directly owns 86,683 shares in the company, valued at $1,368,724.57. The disclosure for this purchase can be found here. Insiders have acquired a total of 25,316 shares of company stock worth $396,806 in the last ninety days. Insiders own 1.88% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “AngioDynamics, Inc. (ANGO) Releases FY18 Earnings Guidance” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2017/07/29/angiodynamics-inc-ango-updates-fy18-earnings-guidance-updated.html.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
